Vanguard Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,127,907 shares of SUPN stock, worth $237 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,127,907
Previous 6,137,541
0.16%
Holding current value
$237 Million
Previous $164 Million
16.38%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SUPN
# of Institutions
283Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$402 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$197 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$111 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$102 Million0.09% of portfolio
-
State Street Corp Boston, MA2.16MShares$83.3 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.07B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...